272 related articles for article (PubMed ID: 24627109)
1. Dopamine receptor mapping with PET imaging in Parkinson's disease.
Niccolini F; Su P; Politis M
J Neurol; 2014 Dec; 261(12):2251-63. PubMed ID: 24627109
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in PET imaging for evaluation of Parkinson's disease.
Sioka C; Fotopoulos A; Kyritsis AP
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1594-603. PubMed ID: 20107789
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
de Natale ER; Niccolini F; Wilson H; Politis M
Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
[TBL] [Abstract][Full Text] [Related]
5. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
6. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
7. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
[TBL] [Abstract][Full Text] [Related]
8. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
[TBL] [Abstract][Full Text] [Related]
9. Nigrostriatal and Mesolimbic D
Stark AJ; Smith CT; Lin YC; Petersen KJ; Trujillo P; van Wouwe NC; Kang H; Donahue MJ; Kessler RM; Zald DH; Claassen DO
J Neurosci; 2018 Mar; 38(13):3230-3239. PubMed ID: 29483278
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
11. No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
Schöls L; Reimold M; Seidel K; Globas C; Brockmann K; Hauser TK; Auburger G; Bürk K; den Dunnen W; Reischl G; Korf HW; Brunt ER; Rüb U
Brain; 2015 Nov; 138(Pt 11):3316-26. PubMed ID: 26362908
[TBL] [Abstract][Full Text] [Related]
12. Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?
Villalba RM; Smith Y
Neuroscience; 2013 Oct; 251():2-20. PubMed ID: 23867772
[TBL] [Abstract][Full Text] [Related]
13. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
14. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.
Shen LH; Liao MH; Tseng YC
J Biomed Biotechnol; 2012; 2012():259349. PubMed ID: 22570524
[TBL] [Abstract][Full Text] [Related]
17. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
19. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model.
Liu Y; Hao S; Yang B; Fan Y; Qin X; Chen Y; Hu J
Biochem Pharmacol; 2017 Sep; 140():115-123. PubMed ID: 28551099
[TBL] [Abstract][Full Text] [Related]
20. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]